Round Rock Advisors LLC Makes New $572,000 Investment in DENTSPLY SIRONA Inc. $XRAY

Round Rock Advisors LLC acquired a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 53,922 shares of the medical instruments supplier’s stock, valued at approximately $572,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in DENTSPLY SIRONA in the 1st quarter worth approximately $26,000. Goldman Sachs Group Inc. boosted its stake in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares during the period. Empowered Funds LLC grew its holdings in shares of DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after buying an additional 41,579 shares during the period. Finally, Focus Partners Wealth increased its stake in shares of DENTSPLY SIRONA by 59.1% in the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after buying an additional 9,355 shares during the period. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Price Performance

XRAY stock opened at $11.29 on Thursday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. The firm has a 50 day moving average price of $12.14 and a 200-day moving average price of $11.68. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $14.86. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -4.11, a PEG ratio of 1.37 and a beta of 0.84.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business’s revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities research analysts forecast that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on XRAY shares. Barclays increased their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research report on Monday, August 24th. Piper Sandler increased their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. BMO Capital Markets reissued a “market perform” rating and issued a $13.00 target price on shares of DENTSPLY SIRONA in a research note on Friday, August 7th. Barrington Research set a $15.00 price target on DENTSPLY SIRONA in a report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $13.54.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Michael J. Barber purchased 15,175 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $9.88 per share, with a total value of $149,929.00. Following the acquisition, the director owned 55,943 shares in the company, valued at approximately $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Brian T. Gladden purchased 9,985 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was bought at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the purchase, the director owned 61,849 shares in the company, valued at approximately $619,726.98. This represents a 19.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 35,160 shares of company stock worth $351,179. Company insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.